This brand name is authorized in France
The drug THERALENE contains one active pharmaceutical ingredient (API):
|
1
Alimemazine
UNII 362NW1LD6Z - TRIMEPRAZINE TARTRATE
|
|
Alimemazine has a central sedative effect, comparable to that of chlorpromazine, but largely devoid of the latter’s antiadrenaline action. It has powerful antihistamine and anti-emetic actions. Alimemazine is used to treat neurosis, depression and anxiety of different origins. It prevents and relieves allergic conditions, which cause pruritus and urticaria by blocking histamine produced by the body during an allergic reaction. Alimemazine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| R06AD01 | Alimemazine | R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AD Phenothiazine derivatives |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: FR | Base de données publique des médicaments | Identifier(s): 66801066, 67410412 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
